Gilles Freyer


Ontology type: schema:Person     


Person Info

NAME

Gilles

SURNAME

Freyer

Publications in SciGraph latest 50 shown

  • 2022-03-31 Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era in BRITISH JOURNAL OF CANCER
  • 2022-01-08 Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2020-06-04 Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-06-15 Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-12-14 Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-03-22 Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-03-05 First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts’ Prescribing Practices and Systematic Literature Review in CLINICAL DRUG INVESTIGATION
  • 2016-03-05 Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy in CLINICAL PHARMACOKINETICS
  • 2016 Chemotherapy: First-Line Strategy in OVARIAN CANCER IN ELDERLY PATIENTS
  • 2016 Biological Research: Current Directions in OVARIAN CANCER IN ELDERLY PATIENTS
  • 2015-09-21 Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-08-28 Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia in MEDICAL ONCOLOGY
  • 2015-07-04 Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods in BMC RESEARCH NOTES
  • 2014-06-06 Prédiction de la résistance à la chimiothérapie des tumeurs trophoblastiques gestationnelles (TTG) de bas risque par l’analyse de la cinétique des hCG in ONCOLOGIE
  • 2014-02-20 Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients in BRITISH JOURNAL OF CANCER
  • 2014-01-13 Hypersensitivity to oxaliplatin: clinical features and risk factors in BMC PHARMACOLOGY AND TOXICOLOGY
  • 2013-11-20 Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand–foot syndrome (HFS) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-04-16 Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements in BRITISH JOURNAL OF CANCER
  • 2012-12-13 Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study in TARGETED ONCOLOGY
  • 2012-10-17 Pharmacodynamic Models for Discrete Data in CLINICAL PHARMACOKINETICS
  • 2012-07-24 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Persistent and Recurrent Advanced Ovarian Carcinoma: A Multicenter, Prospective Study of 246 Patients in ANNALS OF SURGICAL ONCOLOGY
  • 2012-07-12 Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2012-04-24 Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours in BRITISH JOURNAL OF CANCER
  • 2012 Traitement adjuvant du cancer du sein sans envahissement ganglionnaire de la patiente âgée de plus de 70 ans in CANCER DU SEIN
  • 2011-11-08 Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs in BMC CANCER
  • 2011-10 Le cancer du sein de la femme âgée (hors situation métastatique) in ONCOLOGIE
  • 2011-08-02 Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2011-03-11 La prime jeunesse de l’oncogériatrie in ONCOLOGIE
  • 2010-10-21 Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model in PHARMACEUTICAL RESEARCH
  • 2010-09-02 Influence of Dosing Schedule on Organ Exposure to Cyclosporin in Pediatric Hematopoietic Stem Cell Transplantation: Analysis with a PBPK Model in PHARMACEUTICAL RESEARCH
  • 2010-07-06 La chimiothérapie métronomique du cancer du sein métastatique: à propos d’un cas in ONCOLOGIE
  • 2009-06 Recherche clinique en oncogériatrie in ONCOLOGIE
  • 2008-12-24 An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 2008-11-20 Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study in BREAST CANCER RESEARCH AND TREATMENT
  • 2008-01 Spécificité du cancer de l’ovaire chez la personne âgée in ONCOLOGIE
  • 2007-05 Exposure-Effect Population Model of Inolimomab, a Monoclonal Antibody Administered in First-Line Treatment for Acute Graft-Versus-Host Disease in CLINICAL PHARMACOKINETICS
  • 2003-09-01 Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures in ANNALS OF SURGICAL ONCOLOGY
  • 2000-07-25 Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure in BRITISH JOURNAL OF CANCER
  • 1999-02 A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1997-09 Pancreatic neuroendocrine carcinoma metastatic to the breast as part of the multiple endocrine neoplasia type 1 syndrome in ENDOCRINE PATHOLOGY
  • 1996-05 Quality of final care for terminal cancer patients in a comprehensive cancer centre from the point of view of patients' families in SUPPORTIVE CARE IN CANCER
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.413852.9", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417829.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.488279.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410458.c", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.417812.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5399.6", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.25697.3f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.419188.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5596.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.7849.2", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.411430.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.440383.8", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413156.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.420061.1", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.248762.d", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.413746.3", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.51462.34", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.476192.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.410569.f", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.412354.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.486422.e", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.418113.e", 
            "type": "Organization"
          }
        ], 
        "familyName": "Freyer", 
        "givenName": "Gilles", 
        "id": "sg:person.0636233052.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636233052.33"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-12-01T07:13", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/person/person_907.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0636233052.33'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0636233052.33'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0636233052.33'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0636233052.33'


     

    This table displays all metadata directly associated to this object as RDF triples.

    60 TRIPLES      10 PREDICATES      33 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0636233052.33 schema:affiliation N4fc0e90d86d940c9b99774198fc18202
    2 grid-institutes:grid.248762.d
    3 grid-institutes:grid.25697.3f
    4 grid-institutes:grid.410458.c
    5 grid-institutes:grid.410569.f
    6 grid-institutes:grid.411430.3
    7 grid-institutes:grid.412354.5
    8 grid-institutes:grid.413156.4
    9 grid-institutes:grid.413746.3
    10 grid-institutes:grid.417812.9
    11 grid-institutes:grid.417829.1
    12 grid-institutes:grid.418113.e
    13 grid-institutes:grid.418116.b
    14 grid-institutes:grid.419188.d
    15 grid-institutes:grid.420061.1
    16 grid-institutes:grid.440383.8
    17 grid-institutes:grid.476192.f
    18 grid-institutes:grid.486422.e
    19 grid-institutes:grid.488279.8
    20 grid-institutes:grid.51462.34
    21 grid-institutes:grid.5399.6
    22 grid-institutes:grid.5596.f
    23 grid-institutes:grid.7849.2
    24 schema:familyName Freyer
    25 schema:givenName Gilles
    26 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636233052.33
    27 schema:sdDatePublished 2022-12-01T07:13
    28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    29 schema:sdPublisher Ncbe76b2dc5ae42ada49095c6bdb1beb9
    30 sgo:license sg:explorer/license/
    31 sgo:sdDataset persons
    32 rdf:type schema:Person
    33 N4fc0e90d86d940c9b99774198fc18202 schema:affiliation grid-institutes:grid.413852.9
    34 sgo:isCurrent true
    35 rdf:type schema:OrganizationRole
    36 Ncbe76b2dc5ae42ada49095c6bdb1beb9 schema:name Springer Nature - SN SciGraph project
    37 rdf:type schema:Organization
    38 grid-institutes:grid.248762.d schema:Organization
    39 grid-institutes:grid.25697.3f schema:Organization
    40 grid-institutes:grid.410458.c schema:Organization
    41 grid-institutes:grid.410569.f schema:Organization
    42 grid-institutes:grid.411430.3 schema:Organization
    43 grid-institutes:grid.412354.5 schema:Organization
    44 grid-institutes:grid.413156.4 schema:Organization
    45 grid-institutes:grid.413746.3 schema:Organization
    46 grid-institutes:grid.413852.9 schema:Organization
    47 grid-institutes:grid.417812.9 schema:Organization
    48 grid-institutes:grid.417829.1 schema:Organization
    49 grid-institutes:grid.418113.e schema:Organization
    50 grid-institutes:grid.418116.b schema:Organization
    51 grid-institutes:grid.419188.d schema:Organization
    52 grid-institutes:grid.420061.1 schema:Organization
    53 grid-institutes:grid.440383.8 schema:Organization
    54 grid-institutes:grid.476192.f schema:Organization
    55 grid-institutes:grid.486422.e schema:Organization
    56 grid-institutes:grid.488279.8 schema:Organization
    57 grid-institutes:grid.51462.34 schema:Organization
    58 grid-institutes:grid.5399.6 schema:Organization
    59 grid-institutes:grid.5596.f schema:Organization
    60 grid-institutes:grid.7849.2 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...